Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Risperidone Market Growth Analysis: How Will Revenue Trend Over The Forecast Period?
The risperidone market size has seen robust growth in recent years. It is anticipated to expand from $7.7 billion in 2025 to $8.3 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.8%. The reasons for this historical growth include the increasing prevalence of schizophrenia and bipolar disorder, widespread clinical acceptance of atypical antipsychotics, the availability of generic risperidone formulations, the expansion of mental health treatment programs, and improved psychiatric diagnosis rates.
The risperidone market is projected to experience substantial expansion in the coming years, reaching $11.13 billion in 2030 at a compound annual growth rate (CAGR) of 7.6%. This anticipated growth during the forecast period is fueled by several factors, including a heightened demand for long-acting antipsychotic injections, an increased emphasis on personalized psychiatric care, the broadening of community mental health services, the expanding adoption of digital mental health monitoring, and an expanding elderly patient demographic. Key trends observed over the forecast period encompass a rising preference for long-acting injectable formulations, the increasing application of extended-release tablets, a stronger emphasis on solutions for patient adherence, the development of expanded pediatric and geriatric dosage forms, and improved monitoring of treatment outcomes.
Get A Free Sample Report With In-Depth Market Insights:
Risperidone Market Growth Factors Behind Sustained Expansion
The anticipated expansion of the risperidone market is directly linked to the rising occurrence of mental health conditions. These conditions encompass a broad spectrum of issues that affect an individual’s mood, thought processes, and behavior, often resulting in significant distress or impairment in daily functioning. The increasing prevalence of mental health disorders primarily stems from elevated stress levels and modern lifestyle changes that disrupt emotional equilibrium, sleep patterns, and overall psychological well-being. Risperidone effectively assists in managing these disorders by balancing neurotransmitters in the brain, which in turn reduces symptoms such as agitation, hallucinations, and mood swings, thereby supporting overall emotional stability. For instance, in March 2023, the Alzheimer’s Association, a US-based nonprofit voluntary health organization, reported that in 2023, approximately 6.7 million Americans aged 65 and older are living with Alzheimer’s dementia, a number projected to rise to 13.8 million by 2060. Consequently, the escalating incidence of mental health disorders is a key driver for the growth of the risperidone market.
Risperidone Market Segmentation And Category Overview
The risperidone market covered in this report is segmented –
1) By Product Type: Tablets, Oral Solution, Injectable
2) By Patient Age Group: Pediatric Patients, Adult Patients, Elderly Patients
3) By Application: Schizophrenia, Bipolar Disorder, Autism, Other Applications
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Clinic Pharmacies
5) By End-Users: Hospitals, Homecare, Specialty Clinics, Ambulatory Surgical Centers, Other End Users
Subsegments:
1) By Tablets: Standard Release, Extended Release, Orally Disintegrating
2) By Oral Solution: Flavored Solution, Unflavored Solution, Concentrated Solution
3) By Injectable: Long Acting Injection, Short Acting Injection, Depot Injection
Risperidone Market Industry Trends Fueling Future Revenue Growth
Leading companies within the risperidone market are concentrating on creating inventive solutions, such as long-acting injectable formulations, to enhance patient adherence and improve treatment results. These long-acting injectable formulations are specifically designed medications that progressively release risperidone over time, enabling less frequent administration while sustaining consistent therapeutic effects. As an illustration, in January 2023, Luye Pharma Group Ltd., a pharmaceutical company based in China, obtained approval from the U.S. Food and Drug Administration (FDA) for Rykindo (risperidone). This extended-release injectable formulation is intended for the treatment of schizophrenia in adults, and for use as either monotherapy or in conjunction with lithium or valproate for the ongoing treatment of bipolar I disorder in adults. This biweekly intramuscular risperidone injection leverages Luye Pharma’s advanced microsphere technology, facilitating a long-acting, sustained-release delivery that helps manage symptoms in both schizophrenia and bipolar I disorder. The formulation offers a swift onset of action for rapid symptom alleviation and allows for quick elimination post-discontinuation, providing healthcare professionals greater adaptability in tailoring treatment plans to individual patient requirements.
Risperidone Market Competitive Analysis Of Leading Industry Participants
Major companies operating in the risperidone market are Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Sun Pharmaceutical Industries Ltd., Apotex Inc., Cipla Limited., Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals PLC, Zydus Cadila Healthcare Ltd, Alkem Laboratories Ltd., Amneal Pharmaceuticals LLC, Natco Pharma Limited., Strides Pharma Science Limited., RPG Life Sciences Limited., Jubilant Cadista Pharmaceuticals Inc., ICROM S.p.A., Accord Healthcare Ltd., Ambica Pharma Machines Pvt. Ltd., Gonane Pharma Private Limited., Janssen Pharmaceuticals, LGM Pharma
View The Full Risperidone Market Report:
Risperidone Market Regional Distribution: Which Areas Power Market Growth?
North America was the largest region in the risperidone market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the risperidone market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
